LGALS14

Across TCGA pan-cancer cohorts, LGALS14 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LGALS14 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LGALS14 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LGALS14 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, UCEC, and HNSC are the cancer types where LGALS14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.604	0.974	<.001	80	view →
UCEC	DFS	Median	II,III,IV	0.348	1.000	<.001	62	view →
HNSC	DFS	Median	All	0.532	0.780	.001	41	view →
PDAC	DFS	Quartile	III,IV	0.912	0.357	.003	16	view →
LSCC	OS	Tertile	II,III,IV	0.538	0.946	.003	11	view →
LUAD	DFS	Tertile	II,III,IV	0.806	0.928	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LGALS14–CCRCC (OS)

Open the CCRCC breakdown →